Causative organisms

Chlamydia trachomatis (20-50%), Mycoplasma genitalium (10-25%), or adenovirus, Trichomonas vaginalis, herpes simplex virus (<10%).

A pathogen is often not identifiable (30-60%). Testing for Ureaplasma species is not recommended.

Incubation period Depending on the organism
How far to trace back See relevant sections if C. trachomatis or M. genitalium are isolated
Usual testing method C. trachomatis and M. genitalium nucleic acid amplification testing (NAAT) Consider NAAT testing for adenovirus, T. vaginalis or herpes simplex virus if clinically indicated.
Common symptoms Dysuria, urethral discharge
Likelihood of transmission per act of unprotected intercourse Depends on specific pathogen
Likelihood of long-term sexual partner being infected Depends on specific pathogen
Protective effect of condoms High for sexually transmitted pathogens
Transmission by oral sex May be relevant for C. trachomatis
Duration of potential infectivity Depends on specific pathogen
Important sequelae If untreated, may lead to epididymo-orchitis or infection of sexual partner(s) with a vagina with increased risk for pelvic inflammatory disease
Direct benefit of detection and treatment of contacts Cure where a treatable pathogen is found
Usual management of contacts Counselling, clinical examination, test for C. trachomatis and M. genitalium if index patient is positive. Consider presumptively treating sexual contacts — see national STI guidelines
Contact tracing priority High — Where C. trachomatis or M. genitalium is detected in the index patient

Trichomoniasis is notifiable in Northern Territory

Page last updated April 2021